Abstract. Schizandrin A (SchA) can be extracted from the vine plant Schisandra chinensis and has been reported to confer various biologically active properties. However, its potential biological effects on non-small cell lung cancer (NSCLC) remain unknown. Therefore, the present study aims to address this issue. NSCLC and normal lung epithelial cell lines were first treated with SchA. Cell viability and proliferation were measured using CellTiter-Glo Assay and colony formation assays, respectively. PI staining was used to measure cell cycle distribution. Cell cycle-related proteins p53, p21, cyclin D1, CDK4, CDK6, cyclin E1, cyclin E2, CDK2 and DNA damage-related protein SOX4 were detected by western blot analysis. Annexin V-FITC/PI staining, DNA electrophoresis and Hoechst 33342/PI dual staining were used to detect apoptosis. JC-1 and DCFH-DA fluorescent dyes were used to measure the mitochondrial membrane potential and reactive oxygen species concentrations, respectively. Apoptosis-related proteins caspase-3, cleaved caspase-3, poly(ADP-ribose) polymerase (PARP), cleaved PARP, BimEL, BimL, BimS, Bcl2, Bax, caspase-9 and cleaved caspas-9 were measured by western blot analysis. Dansylcadaverine was used to detect the presence of the acidic lysosomal vesicles. The expression levels of the autophagy-related proteins LC3-I/II, p62/SQSTM and AMPKα activation were measured using western blot analysis. In addition, the autophagy inhibitor 3-methyladenine was used to inhibit autophagy. SchA was found to reduce NSCLC cell viability whilst inhibiting cell proliferation. Low concentrations of SchA (10-20 µM) mainly induced G1/S-phase cell cycle arrest. By contrast, as the concentration of SchA increased (20-50 µM), cells underwent apoptosis and G2/M-phase cell cycle arrest. As the treatment concentration of SchA increased from 0 to 50 µM, the expression of p53 and SOX4 protein also concomitantly increased, but the expression of p21 protein was increased by 10 µM SchA and decreased by higher concentrations (20-50 µM). In addition, the mRNA and protein expression levels of Bcl-like 11 (Bim) EL, BimL and BimS increased following SchA application. SchA induced the accumulation of acidic vesicles and induced a marked increase in the expression of LC3-II protein, suggesting that SchA activated the autophagy pathway. However, the expression of the p62 protein was found to be increased by SchA, suggesting that p62 was not degraded during the autophagic flux. The 3-methyladenine exerted no notable effects on SchA-induced apoptosis. Taken together, results from the present study suggest that SchA exerted inhibitory effects on NSCLC physiology by inducing cell cycle arrest and apoptosis. In addition, SchA partially induced autophagy, which did not result in any cytoprotective effects.

Introduction

According to the ‘World Cancer Report 2020’ released by the World Health Organization International Agency for Research on Cancer, lung cancer (1.8 million cases per year) remains to be the leading cause of cancer-associated mortality (1). Non-small cell lung cancer (NSCLC), including lung squamous cell carcinoma, lung adenocarcinoma and large cell carcinoma, is the most common type of lung cancer, accounting for ~85% of all cases (2). Significant progress has been achieved in the development of treatment methods for NSCLC over the past decade. The clinical application of molecularly targeted drugs, including gefitinib, osimertinib, crizotinib and loratadinib and immune checkpoint inhibitors, such as nivolumab and pembrolizumab, has significantly prolonged the survival time of patients with advance NSCLC (3,4). However, NSCLC cells can develop resistance to these targeted therapy or immunotherapy, thereby resuming disease progression (5-7). Therefore, drug resistance has become a major obstacle to the survival of patients with NSCLC (5-7). At present the primary strategy to address drug resistance is by either combining multiple antitumor agents or by identifying novel therapeutic agents specifically targeting the mechanism underlying drug resistance.
resistance (8-10). However, adverse side effects following multi-drug therapy limit its clinical application (10,11). Therefore, investigating novel effective therapeutic strategies is essential for overcoming drug resistance and prolonging the survival of patients with lung cancer.

By gaining an in-depth understanding of the cancer pathological mechanism, targeted therapeutic drugs can be designed and developed based on the specific physiological characteristics of the cancer (12). However, screening existing compounds or naturally occurring medicinal compounds for potential therapeutic effects on cancer remains to be an indispensable part of cancer treatment research. Vinblastine (13), platinum compounds (14) and paclitaxel (15) are all examples of anti-cancer agents that can be found naturally. In addition, monomer compounds purified from natural products also form part of the drug screening libraries (16-18). Their biological activities on various processes, including inflammation, infection and cancer development, have been extensively investigated (19).

Schizandrin A (SchA), also known as deoxyschizandrin, is one of the most biologically active lignans isolated from the fruit of the medicinal vine plant Schisandra chinensis (20). Wang et al previously revealed that male Sprague-Dawley rats fed with an extract of Schisandra chinensis (50 mg/kg) retained detectable levels of SchA in the plasma 6 h after feeding (21). Since SchA has symmetrical methoxy and methyl groups, the loss of these groups forms part of the catabolic mechanism of SchA when it is broken down (22). Based on the results from another pharmacokinetic study into Schizandrol A, Liu et al (23) found that hydroxylation and demethylation may also occur when SchA is broken down.

Previous pharmacological studies have reported that SchA has a variety of biologically active properties. Anti-inflammatory (24-27) and antiviral effects (28,29) of SchA and its analogs were initially found. However, it was subsequently found that SchA also confers antitumor (30,31), anti-allergy (32) and anti-fibrosis (33) effects whilst enhancing immunity (34). Over the past decade, studies investigating the potential antitumor effects of SchA have been gradually increasing. It was previously reported that SchA can inhibit cell proliferation, induce cell apoptosis, inhibit cell invasion and tumor metastasis in breast cancer, ovarian cancer, choriocarcinoma, thyroid cancer and colorectal cancer (31,35-42), in addition to enhancing drug efficacy in NSCLC and colon carcinoma (43,44) or overcome drug resistance in breast cancer and esophageal carcinoma (43,45,46) In particular, Xian et al revealed that SchA combined with gefitinib could inhibit proliferation whilst promoting apoptosis in gefitinib-resistant NSCLC cells (43). However, the underlying mechanistic effects of SchA on NSCLC remain poorly understood. Therefore, the potential biological effects of SchA on NSCLC was investigated in the present study.

Materials and methods

Cell culture and treatment. The human NSCLC cell lines A549, H1299 and H1975 and the normal human lung epithelial cell lines BEAS-2B were purchased from The Cell Bank of Type Culture Collection of The Chinese Academy of Sciences. RPMI-1640 medium and PBS were purchased from Corning, Inc. and FBS was purchased from PAN-Biotech GmbH (cat. no. P30-3302). All cell lines were cultured in RPMI-1640 medium supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO₂. SchA, with a purity of >98%, was purchased from Chengdu Must Bio-Technology Co., Ltd. (cat. no. 19092908). SchA was dissolved DMSO at a concentration of 50 mM for subsequent experiments.

Cell viability assay. The A549, H1299, H1975 and BEAS-2B cell lines were seeded into a 96-well plate at a density of 3,000 cells per well and incubated at 37°C overnight. For concentration dependence experiments, different concentrations of SchA (0, 25, 50, 75 and 100 µM) or an equal volume of DMSO were added to the cell culture medium to treat the cells for 24 h at 37°C. For time dependence experiments, the cells were treated with 50 µM SchA for 0, 12, 24, 36 and 48 h at 37°C. A Cell Titer-Glo Luminescence Viability Assay kit (cat. no. G7571; Promega Corporation) was used to detect cell viability according to the manufacturer's protocol. Each concentration and time dependence assay was repeated three times. The IC₅₀ and its 95% confidence interval of SchA was evaluated using best-fit dose-response inhibition curves with GraphPad Prism v7.0 Software (GraphPad Software, Inc.).

Cell colony formation assay. The effect of SchA on cell colony formation was evaluated using colony formation assays. Single-cell suspensions of A549 and H1975 were seeded into a six-well plates at a density of 800 cells/well. After the cells adhered, SchA at concentrations of 0, 25 and 50 µM was added into the culture medium. The cells were placed in an incubator and cultured for 10-14 days at 37°C until a single cell clone was counted using ImageJ v2 software (ImageJ; National Institutes of Health).

Cell cycle analysis using flow cytometry. The cells were trypsinized with trypsin and centrifuged at 300 x g for 3 min at room temperature, before being re-suspended in 1 ml pre-chilled 70% ethanol. After fixation overnight at -20°C, the cells were re-suspended and stained with 500 µl PI/RNase staining buffer (cat. no. 550825; BD Biosciences) at a density of 1x10⁶ cells/ml at room temperature for 30 min. The cells were then detected using a CytoFLEX analysis flow cytometer (Beckman Coulter, Inc.) and the FL2-A: B610-ECD channel. The results were analyzed using the FlowJo v10 software (FlowJo LLC).

Cell apoptosis analysis using flow cytometry. After the A549 and H1975 cells were treated with SchA (0, 25 and 50 µM) for 24 h at 37°C, the cells were trypsinized without EDTA (cat. no. CR27250; Guangzhou Ruisen Biotechnology Co., Ltd.). After washing twice with pre-chilled PBS, the cells were re-suspended in 1X buffer provided in the FITC Annexin V Apoptosis Detection kit (cat. no. 556547; BD Biosciences) to a density of 5 x 10⁶ cells/ml. Next, 100 µl cell suspension was added to a flow cytometry tube and 5 µl Annexin V-FITC and 5 µl PI staining solution (cat. no. 556547; BD Biosciences) was added.
The samples were incubated at room temperature for 15 min in the dark, before 400 µl 1X buffer provided in the kit was added. A CytoFLEX analysis flow cytometer (Beckman Coulter, Inc.) and the FL1-A: B525-FITC and FL4-A: Y585-PE channels were used to measure cell apoptosis, where the results were analyzed using the FlowJo v10 software (FlowJo LLC).

The A549 and H1975 cells were also treated with 5 mM 3-MA for 4 h at 37°C and then treated with 50 µM SchA for 24 h at 37°C. The apoptosis of the cells was measured by the FITC Annexin V Apoptosis Detection kit (cat. no. 556547; BD Biosciences) and a CytoFLEX analysis flow cytometer (Beckman Coulter, Inc.). The results of apoptosis were also analyzed using the FlowJo v10 software (FlowJo LLC).

Detection of reactive oxygen species (ROS). The single-cell suspensions of A549 and H1975 were seeded into a six-well plates at a density of 2x10^5 cells/well. The cells were treated with SchA (0, 25 and 50 µM) for 24 h at 37°C, then ROS probe DCFH-DA (cat. no. 287810; Sigma-Aldrich; Merck KGaA) was added to the cell culture medium at 1:1,000 before the cells were incubated at 37°C for 20 min and washed twice with PBS. Intracellular ROS levels were detected using a fluorescence microscope at x200 magnification (Leica Microsystems GmbH).

After the cells were treated with SchA (0, 25 and 50 µM) for 24 h at 37°C, the cells were trypsinized to form a single cell suspension with trypsin and re-suspended. The cells were re-suspended in medium containing 0.1% DCFH-DA at a density of 1x10^6 cells/ml and incubated at 37°C for 20 min. They were then washed twice with PBS and re-suspended with 500 µl PBS after centrifugation at 240 x g for 3 min at 37°C. The FL1-A: B525-FITC channel in a CytoFLEX analysis flow cytometer (Beckman Coulter, Inc.) was used to detect the level of intracellular ROS. The flow cytometry data was analyzed using the FlowJo v10 software (FlowJo LLC).

Staining with Dansylcadaverine (MDC) and Hoechst 33342. MDC was purchased from Sigma-Aldrich (cat. no. 1021-91-2; Sigma-Aldrich; Merck KGaA). The single-cell suspensions of A549 and H1975 were seeded into a six-well plates at a density of 2x10^5 cells/well. After treatment with SchA (0, 25, 50 µM) for 24 h at 37°C, the cells were washed twice with PBS and incubated with MDC (final concentration, 0.05 mM) and Hoechst 33342 (final concentration, 1 µg/ml) for 15 min at room temperature in the dark. After washing the cells three times with PBS, the green and blue fluorescence emitted by the cells, was observed. Images were captured using a fluorescence microscope at x200 magnification (Leica Microsystems GmbH). Image-Pro Plus v6.0 software (Media Cybernetics, Inc.) was used to merge the monochrome fluorescence images. Autophagy inhibitor 3-methyladenine (3-MA) was purchased from Sigma-Aldrich (cat. no. M9281; Sigma-Aldrich; Merck KGaA).

Measurement of ATP levels. The ATP levels were assessed by ATP Detection Assay kit (cat. no. 700410, Cayman Chemical Company) according to the manufacturer's protocols. The single-cell suspensions of A549 and H1975 were seeded into a six-well plates at a density of 2x10^5 cells/well. The cells were treated with SchA (0, 25 and 50 µM) for 24 h at 37°C, the cell culture medium was first discarded and the cells were washed with pre-chilled PBS before 1 ml 1X sample buffer was added to each well (6-well plate) to lyse the cells. D-luciferin and luciferase were added to the ATP detection buffer to prepare the reaction mixture. The detection holes on the black 96-well plates and three duplicate wells for each sample were organized. A total of 100 µl freshly prepared reaction mixture and 10 µl cell lysate were added to each well, mixed and incubated for 15 min in the dark at room temperature. A multifunctional microplate reader was used to measure the fluorescence value in each well. GraphPad Prism v7.0 software (GraphPad Software, Inc.) was used to generate a histogram to show the fluorescence values.

Western blot analysis. The cells were lysed using the RIPA Lysis Buffer (cat. no. P0013B; Beyotime Institute of Biotechnology)
containing the Protease Inhibitor Cocktail (cat. no. 05892791001; Roche Diagnostics GmbH) and Phosphatase Inhibitor Cocktail (cat. no. 524629; EMD Millipore). The BCA Protein Assay kit (cat. no. PC0020; Beijing Solarbio Science & Technology Co., Ltd.) was used to determine protein concentration. Loading buffer (5X) was then added to the protein lysate at a ratio of 1:4. A total of 30 µg protein sample per lane was separated using 12% SDS-PAGE and then transferred onto PVDF membranes (EMD Millipore). The membranes were blocked with 5% BSA (cat. no. 97061-422; VWR International) in TBS-0.1% Tween-20 (TBST) before being incubated with primary antibodies on a shaker overnight at 4˚C. The p53 (cat. no. 2527), p21 (cat. no. 2947), cyclin D1 (cat. no. 2922), CDK4 (cat. no. 12790), CDK6 (cat. no. 13331), cyclin E1 (cat. no. 20808), cyclin E2 (cat. no. 4132), caspase-3 (cat. no. 14220), poly (ADP-ribose) polymerase (PARP; cat. no. 9542), Bcl2-like 11 (Bim; cat. no. 2933), Bcl2 (cat. no. 4223), Bax (cat. no. 5023), caspase-9 (cat. no. 9502), LC3 (cat. no. 4108), p62 (cat. no. 8025), phosphorylated (p) AMPKα-T172 (cat. no. 2535) and AMPKα (cat. no. 5831) antibodies were purchased from Cell Signaling Technology, Inc. The primary antibodies against SOX4 (cat. no. DF2610; Affinity Biosciences) and β-actin (cat. no. A1978; Sigma-Aldrich; Merck KGaA) were also used. All primary antibodies were diluted in primary antibody dilution buffer (cat. no. P0256; Beyotime Institute of Biotechnology) at a ratio of 1:1000. The membrane was washed three times with TBST and then incubated with HRP-conjugated anti-rabbit (cat. no. 7074; Cell Signaling Technology, Inc.) or anti-mouse (cat. no. 7076; Cell Signaling Technology, Inc.) secondary antibodies at room temperature for 1 h. After washing the membrane three times with TBST, an ECL kit chemiluminescent substrate (cat. no. BL523B; Biosharp Life Sciences) was used to visualize the protein bands.

Total RNA extraction and PCR. Total RNA was extracted using a RNA Quick Purification kit (cat. no. ES-RN001; Shanghai YiShan Biotechnology Co., Ltd.) and reverse transcribed into single-strand cDNA using a HiScript II Q RT SuperMix kit (cat. no. R223; Vazyme Biotechnology Co., Ltd.) at 50˚C for 15 min, followed by 85˚C for 5 sec. Quantitative PCR (qPCR) was performed using the PowerUp™ SYBR™-Green Master Mix (cat. no. A25742; Thermo Fisher Co., Ltd.) and an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Inc.). The thermocycling conditions of qPCR were set as follows: 95˚C for 1 min, followed by 95˚C for 10 sec, 60˚C for 20 sec and 72˚C for 30 sec for 40 cycles. Relative expression levels were calculated by the 2^(-ΔΔCq) method normalized to the internal reference gene β-actin (47).

Reverse transcription (RT)-semi-quantitative PCR (RT-qPCR) was conducted using 2X Taq Master mix (cat. no. P112; Vazyme Biotech Co., Ltd.) and a Bio-Rad T100 thermal cycler (Bio-Rad Laboratories, Inc.). The thermocycling conditions of RT-qPCR were set as follows: 95˚C for 3 min, followed by 95˚C for 15 sec, 60˚C for 15 sec and 72˚C for 60 sec for 25 cycles. The primer sequences were as follows: Bim forward, 5'-TAAGTTCTGTA GTGCGCCGGA-3' and reverse, 5'-GCCTCGTCTCTGTA GGGAGGTAAG-3'; Bim (BimEL, BimL and BimS), which contained exons 2 and 5 (48), forward, 5'-ATGGGCAAAGC AACTCTGCTAG-3' and reverse, 5'-TCAATGCATTCTCCACACA CCA-3' and β-actin forward, 5'-CATGATACGGTCTTATCCCA GGC-3' and reverse, 5'-CTCCTTAATGTCACGCACGAT-3'.

A total of 10 µg DNA per lane was separated using 1% agarose gel and stained with 0.01% Ultra GelRed nucleic acid stain (cat. no. GR501-01; Vazyme Biotech Co., Ltd.).

Statistical analysis. All experiments were repeated 3 times for each assay and the results were presented as the mean ± SD. One-way ANOVA was used to evaluate the quantitative data for statistical significance, then Dunnett’s test was used for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

SchA reduces cell viability and inhibits the proliferation of NSCLC cells. The 2D and 3D structures of SchA (PubChem compound ID, 43595; C24H32O6; molecular weight, 416.5 g/mol) are shown in Fig. 1A and B. SchA belongs to the dibenzo-cyclooctadiene family of lignans (49). Its main feature is that the biaryl units are connected via aliphatic chains to form an eight-membered ring carbon skeleton (50).

The CellTiter-Glo assay was used to measure the viability of cells treated with different concentrations of SchA (0, 25, 50, 75 and 100 µM) for 24 h. The results showed that SchA exerted inhibitory effects on the viability of A549, H1975, H1299 and BEAS-2B cells in a concentration-dependent manner (Fig. 1C). The IC₅₀ and its 95% confidence interval (CI) were used to evaluate the ability of SchA to inhibit cell viability. The IC₅₀ and 95% CI in the A549, H1975, H1299 and BEAS-2B cell lines were 61.09 (44.47-177.0), 101.5 (65.45-529.2), 39.99 (33.48-59.28) and 49.45 (44.84-57.16) µM, respectively. The A549 and H1975 cell lines appeared to be more sensitive to SchA, whilst the H1299 cell line was more resistant. As the treatment time with 50 µM SchA was prolonged (0, 12, 24, 36 and 48 h), the viability of the A549 and H1975 cell lines was also markedly reduced (Fig. 1D). SchA (50 µM) exerted a potent inhibitory effect on the viability of A549 and H1975 cells 24 h after treatment (Fig. 1C and D).

Colony formation assay was used to detect the effect of SchA on cell proliferation and colony formation. The results showed that SchA could significantly inhibit the colony formation abilities of A549 and H1975 cells, where this inhibitory effect was concentration-dependent (Fig. 1E and F).

SchA triggers cell cycle arrest in A549 and H1975 cells. The biological process that is most closely associated with cell proliferation is cell mitosis. Therefore, to investigate the effect of SchA on mitosis, the cell cycle was evaluated using flow cytometry after PI staining. After treatment of A549 and H1975 cells with increasing concentrations of SchA (0, 10, 20, 30 and 50 µM) for 24 h, cell cycle progression was assessed. As shown in Fig. 2A and B, the cells were treated with lower concentrations of SchA (10-20 µM), the percentage of cells in the G₀/G₁ phase was significantly increased. However, after the cells were treated with higher concentrations of SchA (20-50 µM), the percentage of cells in the G₀/G₁ phase was gradually decreased (Fig. 2A and B). Although the percentage of cells in S phase and G2/M phase gradually increased, no statistical significance could be found. In addition, as the concentration of SchA increased, the proportion of cells in the sub-G₁ phase was also significantly increased. This suggests that lower concentrations...
of SchA (10-20 µM) can induce G1/S-phase arrest, whilst higher concentrations of SchA (20-50 µM) can induce apoptosis.

Western blot analysis was subsequently used to measure changes in the expression levels of cell cycle-related proteins. As the concentration of SchA was increased (0, 10, 20, 30 and 50 µM), the protein expression levels of p53, cyclin E2, CDK2 and SOX4 were increased, whilst the protein expression levels of cyclin D1, CDK4, CDK6 and cyclin E1 were decreased (Fig. 2C and D). The protein expression levels of p21 were increased initially, peaking at 10 µM SchA before decreasing again at higher concentrations (Fig. 2C). After the cells were treated with 50 µM SchA for increasing periods time (0, 3, 6, 12 and 24 h), the protein expression levels of p53, cyclin E2, CDK2 and SOX4 were increased, whereas the protein expression levels of p21, cyclin D1, CDK4, CDK6 and cyclin E1 were decreased (Fig. 2D).

**SchA induces apoptosis in A549 and H1975 cells.** Sub-G<sub>t</sub> cells are hypodiploid cells with an incomplete genome (51). SchA was previously found to increase the percentage of sub-G<sub>t</sub> cells whilst also increasing the expression of the DNA damage-related proteins p53 and SOX4 (52). This suggests that DNA damage and apoptosis occurred in the cells following treatment with SchA. In the present study, the percentage of apoptotic cells was detected using flow cytometry and Annexin V-FITC/PI double-staining. The results indicated that the number of early and late apoptotic cells was significantly increased with increasing SchA concentrations (Fig. 3A and B). In addition, DNA electrophoresis was used to detect the effect of SchA on DNA integrity. It was found that SchA treatment caused DNA to break into a characteristic ladder-like pattern (Fig. 3C and D). To investigate the apoptosis-related morphological changes, the SchA-treated cells were stained with Hoechst 33342 and PI before being observed using fluorescence microscopy. The results showed that the cells treated with SchA were shrunken, with evidence of fragmentation and emitted irregular dense masses of blue fluorescence (Fig. 3E and F). In addition, PI red fluorescence was also increased by SchA treatment (Fig. 3E and F).

To verify the effects of SchA on apoptosis on the molecular level, western blot analysis was performed to measure changes in the protein expression levels of apoptosis-related proteins in cells treated with SchA. Following SchA treatment, caspase-3 and PARP in A549 and H1975 cells were cleaved, such that the expression levels of cleaved caspase-3 and cleaved PARP were markedly increased (Fig. 3G and H). These findings suggest that SchA induced apoptosis in A549 and H1975 cells.

**SchA induces the loss of MMP in the NSCLC cell lines.** Mitochondrial damage is one of the key features of apoptotic...
cells, where the loss of MMP is an essential manifestation of mitochondrial damage (53). To investigate the effect of SchA on mitochondrial physiology, JC-1 staining was used to detect the integrity of the MMP in A549 and H1975 cells after treatment with SchA. The red JC-1 aggregates represent intact MMP, whilst green JC-1 monomers represent damaged MMP. As the concentration of SchA increased (0, 25 and 50 µM), the number of cells emitting red fluorescence was decreased, whilst the number of cells emitting green fluorescence was increased (Fig. 4A and B). As a result, there was a significant decrease in the ratio of red (JC-1 aggregates)/green (JC-1 monomers) fluorescence (Fig. 4A and B), suggesting that SchA induced MMP damage in A549 and H1975 cells.

SchA induces changes in the level and distribution of intracellular ROS. Mitochondrial damage leads to impaired oxidative phosphorylation and electron transport chain, which results in excessive ROS production and release from mitochondria (54). Excessive and abnormally distributed ROS can also affect mitochondrial function and reduce cell viability (54). To detect whether the ROS level was affected by SchA, DCFH-DA probes were used to evaluate intracellular ROS levels in the A549 and H1975 cells. The results of DCFH-DA staining were first detected using flow cytometry (Fig. 4C and D). As the concentration of SchA was increased, the number of cells emitting green fluorescence was also markedly and gradually increased, with the green fluorescence intensity strengthening progressively.

The results of DCFH-DA probe staining were also observed using fluorescence microscopy. As shown in Fig. 4E and F, after SchA treatment DCFH-DA green fluorescence in A549 and H1975 cells increased in intensity, which was widely distributed in the cytoplasm. These findings indicate that SchA increased the levels of intracellular ROS and disrupted the distribution of ROS in A549 and H1975 cells.

SchA induces changes in the expression of mitochondrial apoptosis pathway-related proteins. To verify if SchA induces cell apoptosis by activating the mitochondrial pathway, western blot analysis was used to detect the expression levels of mitochondrial apoptosis pathway-related proteins. As shown in Fig. 4G and H, after SchA treatment the expression levels of pro-apoptotic mitochondrial proteins, BimEL, BimL, BimS
and Bax in A549 and H1975 cells were markedly increased. By contrast, the expression level of the anti-apoptotic protein Bcl-2 was decreased. In addition, the expression level of mitochondrial apoptosis biomarker, cleaved-caspase 9 (55), was markedly increased.

Bim is involved in sensing cellular stress and initiates the mitochondrial apoptosis pathway (56). Bim gene transcription typically increases after the cellular stress response and is expressed in the form of various alternative splice variants, including BimEL, BimL and BimS (48,57).
Subsequently, it was found that the protein expression levels of BimEL, BimL, and BimS in the cells were increased after SchA treatment. This may be due to reduced degradation or increased expression of the Bim protein. To detect the effect of SchA on the mRNA expression level of the Bim gene, RT-qPCR was used to detect the mRNA expression levels of Bim. As shown in Fig. 4I, SchA increased the mRNA expression levels of total Bim in A549 and H1975 cells. In addition, the expression of the mRNA levels of BimEL, BimL, and BimS in the A549 and H1975 cells were also measure through RT-PCR. It was found that the mRNA expression levels of BimEL, BimL, and BimS were
also increased after SchA treatment (Fig. 4J). These results suggest that SchA enhanced Bim gene transcription in A549 and H1975 cells.

SchA induces autophagy in A549 and H1975 cells. To investigate the effect of SchA on autophagy in A549 and H1975 cells, they were treated with SchA and stained with MDC and Hoechst 33342. Results were then observed by fluorescence microscopy. In the control cells, Hoechst 33342 emitted weak and uniform blue fluorescence whereas MDC emitted uniform yellow/green fluorescence. In the SchA treated cells, Hoechst 33342 showed irregularly concentrated blue fluorescence whilst MDC showed dense green bodies in the cytoplasm (Fig. 5A and B). The blue fluorescence of Hoechst 33342 and the yellow/green fluorescence intensity of MDC were increased as the SchA concentration was increased (Fig. 5A and B).

In addition, a multifunctional microplate reader was used to detect the fluorescence intensity of the MDC-stained cells. Compared with that in the control cells, the green fluorescence intensity in A549 and H1975 cells treated with SchA was significantly increased (Fig. 5C and D).

To verify that SchA activated the autophagy pathway, western blot analysis was used to evaluate the expression levels of the autophagy-related proteins. The results are shown in Fig. 5G and H. As the concentration of SchA increased, the protein expression levels of LC3, p62 and AMPKα-T172 phosphorylation in A549 and H1975 cells were increased. (H) The protein expression levels of LC3, p62/SQSTM1 and AMPKα-T172 phosphorylation in the A549 and H1975 cells were increased following treatment with 50 µM SchA at different time points. **P<0.01, ***P<0.001 and ****P<0.0001. MDC, dansylcadaverine; SchA, Schizandrin A; ns, non-significant; p, phosphorylated; AMPK, 5’AMP-activated protein kinase.
the degradation of autophagy substrates, specifically the p62 protein.

SchA induces autophagy in A549 and H1975 cells by reducing ATP levels and activating the AMPK pathway. Insufficient energy and ATP production is an important cause of autophagy in cells (60). In the present study, an ATP detection kit was used to detect the effects of SchA on intracellular ATP levels. As shown in Fig. 5E and F, as the concentration of SchA increased, the intracellular ATP levels were significantly decreased. This suggests that SchA reduced the levels of intracellular ATP.

AMPK is a key intracellular energy sensor (61). Changes in the protein levels of pAMPKα-T172 and AMPKα in A549 and H1975 cells after SchA treatment were measured using western blot analysis. It was found that with increasing the concentration and the treatment time of SchA, markedly increased AMPKα-T172 phosphorylation in A549 and H1975 cells (Fig. 5G and H). This indicated that SchA activated the AMPK signaling pathway in these cells, consistent with the finding that SchA reduced the intracellular ATP levels. This reduction in intracellular ATP levels and activation of the AMPK signaling pathway may be the cause of autophagy induction by SchA.

Effect of inhibiting autophagy on SchA-induced apoptosis. Although SchA-treated A549 and H1975 cells exhibited autophagy activation, this process of autophagy did not result in substrate degradation. Commonly used autophagy inhibitors include 3-methyladenine (3-MA), CQ and BafA1 (62). CQ and BafA1 mainly inhibit the fusion of autophagosomes and lysosomes, whereas 3-MA inhibits autophagosome formation (62).

In the present study, the autophagosome formation inhibitor, 3-MA was used to inhibit the early stages of autophagy flux and observe the effects of 3-MA on the cytotoxicity of SchA. After the cells were pre-treated with 3-MA for 4 h, 50 µM SchA was added to treat the cells for 24 h, before apoptosis of the cells was measured using flow cytometry. As shown in Fig. 6A and B, the autophagy inhibitor 3-MA did not induce any significant effects on cell apoptosis induced by SchA. This result suggests that SchA-induced autophagy has little impact on apoptosis.

Discussion

Designing or screening drugs based on the biological characteristics of cancer is an effective method of developing novel strategies for treatment (63). In recent years, numerous studies have shown that SchA has anti-tumor effects. Yan and Guo (35) previously reported that 30 µM SchA could inhibit proliferation, promote apoptosis and inhibit invasion in breast cancer cells. In another study, Xu et al (38) reported that 41.4 µM SchA could inhibit breast cancer cell proliferation and induce cell apoptosis, where the oral administration of SchA (25 mg/kg) could inhibit breast cancer growth in tumor-bearing nude mice. In addition, the weight of the nude mice was not significantly reduced, suggesting that the oral application of SchA was relatively safe (38). Ji and Ma revealed that 50 µM SchA could inhibit choriocarcinoma cell proliferation, invasion and migration whilst inducing apoptosis (36). In addition, Chen et al (37) reported that 68.65 µM SchA could inhibit the proliferation and colony formation by colorectal cancer cells in addition to inducing apoptosis. Ding et al demonstrated that 100 µM SchA could significantly inhibit the proliferation, invasion and migration of thyroid cancer cells (39). Furthermore, Bi et al reported that 30 µM SchA can inhibit the proliferation and invasion of malignant melanoma cells to induce apoptosis (40). In the present study, SchA was found to inhibit the proliferation of NSCLC cells and induced apoptosis. SchA was cytotoxic to the H1975 cell lines at 39.99 µM, whilst higher concentrations (101.5 µM) were required for H1299 cell cytotoxicity. The normal lung epithelial cell line BEAS-2B, was also sensitive
to SchA, which may limit the clinical application of SchA. However, SchA is an important agent for investigation, since it could provide a basic starting point and has the potential for the optimization of more selective and effective, but less toxic derivatives (64).

SchA at low concentrations (10-20 µM) induced G1/S-phase arrest, whereas high concentrations of SchA (≥30 µM) caused cell apoptosis. This suggests that SchA caused DNA damage at low concentrations, but the cells could maintain G1/S-phase arrest to repair the DNA damage. As the concentration of SchA increased and the treatment time was prolonged, the cells gradually lost the ability to maintain the G1/S-phase arrest and entered the S-phase for DNA replication. DNA replication under stress will lead to fatal DNA damage (65,66), causing a large number of cells to be blocked at the G2/M cycle checkpoint and undergo cell death.

At low concentrations of SchA, the expression level of the p21 protein increased and the cells were blocked at the G1/S-phase. As the concentration of SchA increased, the expression level of the p21 protein was decreased, whilst the expression levels of cyclin E2 and CDK2 were increased. This suggest that the increase in p21 may cause SchA-mediated cell G1/S-phase arrest. However, subsequently the reduction in p21 expression and elevated CDK2 and cyclin E2 expression could cause the cells to overcome G1/S-phase arrest and enter the S-phase. In colorectal cancer cells, Rehman et al (67) found that when the colorectal cancer cells were treated with the chemotheray drugs irinotecan or FOLFIRI (5-FU, leucovorin and irinotecan), they would enter a slow-dividing, diapause-like, drug-tolerant persister (DTP) state with low energy consumption to resist chemotherapy. Therefore, it was proposed that a precise attack on cancer cells entering the diapause-like DTP state could be an effective method to overcome cancer resistance to chemotherapy (67). In the present study, it was found that G1/S-phase arrest occurred when the cells were damaged by SchA, thereby preventing the cells from entering the S-phase and subsequent apoptosis. G1/S-phase arrest could also be one of the protection mechanisms of cancer cells (68). Reduction in p21 protein expression and increase in CDK2 and cyclin E2 protein expression could cause DNA-damaged cancer cells to overcome G1/S-phase arrest and enter the S-phase, thereby inducing apoptosis. Therefore, p21, CDK2 and cyclin E2 proteins could potentially be effective targets for overcoming drug resistance in NSCLC cells.

Autophagy is a self-degradation cellular process activated by stress responses, such as starvation, hypoxia or oxidative stress (69). The autophagy mechanism can decompose and recycle intracellular aggregated macromolecular structures or damaged organelles to provide raw materials for the pro-survival metabolic cycle (70). This regulates intracellular homeostasis and assist cells in surviving unfavorable environments (60). Autophagy serves a key role in the development and progression of a variety of tumors, such as lung cancer, breast cancer, stomach cancer, bowel cancer, prostate cancer and pancreatic cancer, and is also one of the main causes of cancer drug resistance (70-75). In the present study, SchA could activate the stress response and induce autophagy in the A549 and H1975 cell lines. However, the autophagy activated by SchA was incomplete, which mainly manifested as the efficient degradation of the autophagy substrate p62.

AMPK is an evolutionarily conserved serine/threonine protein kinase that acts as an energy sensor in cells (76). It serves a crucial role in the activation of catabolism and inactivation of anabolism (61). Under physiological and pathological conditions, AMPK can be phosphorylated by upstream kinases and bind to AMP or ADP instead of ATP, leading to AMPK activation (77). Activated AMPK regulates various metabolic processes, including autophagy (78). AMPK directly promotes autophagy by phosphorylating autophagy-related proteins in the mTOR complex 1, unc-51 like autophagy activating kinase 1 and phosphatidylinositol 3-kinase catalytic subunit type 3 complex, or indirectly promoting autophagy by regulating transcription factors, such as forkhead box O3, transcription factor EB and bromodomain-containing protein 4 (78). In the present study, it was found that SchA reduced the level of intracellular ATP and activated AMPK signaling, which may be one of the mechanisms by which SchA induces autophagy in the NSCLC cell lines.

If autophagy mediates protective effects on cells, then promoting autophagy could inhibit SchA-induced apoptosis and inhibiting autophagy could promote SchA-induced apoptosis. Commonly used inhibitors of autophagy are CQ (79), BafA1 (59), 3-MA (80) and specific and potent autophagy inhibitor-1 (62,81,82). In the present study, the inhibitor 3-MA, which can inhibit the early stage of autophagy (62), was added to inhibit autophagy before the effects of SchA on cell apoptosis was analyzed. It was found that 3-MA did not promote or inhibit SchA-induced cell apoptosis. The present study showed that the incomplete autophagy induced by SchA did not promote cell survival. It was suggested that insufficient autophagy failed to supply recycled materials to sustain pro-survival cellular metabolic processes and maintain homeostasis.

To conclude, the small molecule compound SchA extracted from the medicinal plant Schisandra exerted specific cytotoxic effects on the NSCLC cell lines. When the concentration of SchA is low, it mediated G1/S-phase cell cycle arrest, whilst at higher concentrations SchA it can cause cell apoptosis. Although, SchA can induce autophagy by activating the AMPK signal, the autophagy process induced by SchA remains incomplete and fails to promote cell survival.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LZ and JH designed the study. YW also designed the study and performed the cell viability assays. WL designed the study and performed drug screening and reagent preparation. XW performed the western blotting experiments. HS designed the study and performed the flow cytometry experiments. CH performed the PCR and western blotting experiments. LZ and JH can confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.
Funding

The present study was supported by The Zhejiang Provincial Traditional Chinese Medicine (Integrated Traditional Chinese and Western Medicine) Key Discipline (grant no. 2017-XK-A33), The National Key Research and Development Program (grant no. 2017YFC0113500), The Zhejiang Province Major Science and Technology Special Project Program (grant no. 2020C03058), The Zhejiang Province Lung Tumor Diagnosis and Treatment Technology Research Supported by the Center (grant no. JBXZ-202007) and The Zhejiang Medicine and Health General Research Program (grant no. 2019KY069).

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. International Agency for Research on Cancer (IARC): Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Questions and Answers (Q&A). https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qal. Accessed January 10, 2021.

2. Zheng M: Classification and pathology of lung cancer. Surg Oncol Clin N Am 12: 303‑315, 2003.

3. Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94: 1023‑1040, 2019.

4. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin 71: 7‑33, 2021.

5. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Lococo T, Li PC, Konk不影响manowas V and Kantha B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13: 353‑361, 2007.

6. Ko B, Paucar D and Halmos B: EGFR T790M: Revealing the secrets of a gatekeeper. Lung Cancer (Auckl) 8: 147‑159, 2017.

7. Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non‑small‑cell lung cancer to chemotherapy. Ann NY Acad Sci 76: 882‑894, 1958.

8. Zheng M: Classification and pathology of lung cancer. Surg Oncol Clin N Am 12: 303‑315, 2003.

9. Eisenbraun MA: Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Questions and Answers (Q&A). https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qal. Accessed January 10, 2021.

10. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Halmos B, Paucar D and Halmos B: EGFR T790M: Revealing the secrets of a gatekeeper. Lung Cancer (Auckl) 8: 147‑159, 2017.

11. Zheng M: Classification and pathology of lung cancer. Surg Oncol Clin N Am 12: 303‑315, 2003.

12. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646‑674, 2011.

13. Noble RL, Beer CT and Cutts JH: Role of chance observations in chemotheraphy. Vinca rosea. Ann NY Acad Sci 76: 882‑894, 1958.
36. Xian H, Feng W and Zhang J: Schizandrin A enhances the tumor growth in choriorcicarcinoma cells. J Biochem Mol Toxicol 34: e22455, 2020.

37. Chen BC, Tu SL, Zheng BA, Tu SL, Zheng BA, Dong QJ, Wan ZA and Dai QQ: Schizandrin A exerts inhibition of P65 and Stat3 phosphorylation. Breast Cancer 25: 479-507, 2019.

38. Xu X, Rajamanicham V, Xu X, Xu X, Liu Z, Yan T, Liang G, Guo G, Zhou H, Wang Y, et al: Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway. Biomed Pharmacother 115: 108922, 2019.

57. Bouillet P, Zhang LC, Huang DC, et al: Gene structure alteration - gene structure alteration - autophagy and cancer. Nat Rev Cancer 15: 276‑289, 2015.